Across TCGA pan-cancer cohorts, OR51A7 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of OR51A7’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where OR51A7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types OR51A7 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
PRAD and THCA are the cancer types where OR51A7 tumor–normal differential expression is most reproducible.